• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.15% Nasdaq Up0.36%

    Protalix BioTherapeutics, Inc. (PLX)

    -NYSE MKT
    1.95 Down 0.03(1.52%) Dec 19, 4:01PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Protalix BioTherapeutics, Inc.
    2 Snunit Street
    Science Park
    Carmiel, 21000
    Israel - Map
    Phone: 972 4 988 9488
    Fax: 972 4 988 9489
    Website: http://www.protalix.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:260

    Business Summary 

    Protalix BioTherapeutics, Inc., a biopharmaceutical company, together with its subsidiary, Protalix Ltd., focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system. It offers taliglucerase alfa for injection, which is marketed under the ELELYSO brand name, as an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. The company’s product pipeline includes PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-112, an orally administered glucocerebrosidase enzyme for the treatment of Gaucher patients utilizing oral delivery of the recombinant glucocerebrosidase enzyme produced and encapsulated within carrot cells; and PRX-106, an oral antiTNF, a plant cell expressed recombinant fusion protein combined of the binding domain of the human TNF receptor and an antibody portion, which is being developed for the treatment of certain immune and inflammatory diseases, such as rheumatoid arthritis, colitis, Crohn’s disease, psoriasis, and other autoimmune and inflammatory disorders. Its product pipeline also comprises PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1 under development for the treatment of Cystic Fibrosis, to be administered by inhalation; and PRX-107, a proprietary plant cell recombinant human Alpha1-antitrypsin and others. The company has a collaboration and licensing agreement with Teva Pharmaceutical Industries Ltd. to develop and manufacture two proteins using its ProCellEx protein expression system. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Carmiel, Israel.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Protalix BioTherapeutics, Inc.

    Key Executives 
     PayExercised
    Dr. Yoseph Shaaltiel Ph.D., 60
    Founder and Exec. VP of R&D
    504.00K0.00
    Mr. Yossi Maimon CPA, 43
    Chief Financial Officer, VP, Sec. and Treasurer
    469.00K0.00
    Mr. Tzvi Palash , 57
    Chief Operating Officer
    323.00K0.00
    Dr. Einat Brill Almon Ph.D., 54
    Sr. VP of Product Devel.
    428.00K0.00
    Mr. Moshe Manor , 58
    Chief Exec. Officer and Pres
    N/AN/A
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders